Med henvisning til meddelelse af 9. marts 2026 om, at Lise Bøgelund Jensen har opsagt sin stilling som administrerende direktør i foreningens administrationsselskab, Wealth Fund Partners A/S, har bestyrelsen indgået aftale med en interim administrerende direktør, Michael Frisch. Michael Frisch vil under sin interim-ansættelse fortsat varetage sin rolle som menigt bestyrelsesmedlem i Wealth Fund Partners.
Michael Frisch tiltræder den 1. maj 2026, hvor han sammen med Lise Bøgelund Jensen vil udgøre direktionen frem til hendes fratræden, der, som tidligere oplyst, er senest den 30. juni 2026.
Michael Frisch fortsætter frem til tiltrædelsen af en ny administrerende direktør i selskabet.
Bestyrelsen er i proces med rekrutteringen af en ny administrerende direktør.
Eventuelle henvendelser vedrørende denne meddelelse kan rettes til bestyrelsesforpersonen...
B2Gold Announces Agreement to Sell its 70% Interest in Fingold Joint Venture to Agnico Eagle for US$325 million; B2Gold and Agnico Eagle to Enter into Nunavut Collaboration Agreement
Written by Customer Service on . Posted in Mergers And Acquisitions.
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce that it has entered into a definitive agreement with Agnico Eagle Mines Limited (“Agnico Eagle”), pursuant to which B2Gold has agreed to sell to Agnico Eagle its 70% interest in Fingold Ventures Ltd. (“Fingold”) in exchange for US$325 million in cash (the “Transaction”). In addition, B2Gold and Agnico Eagle have agreed to enter into a collaboration agreement related to their respective gold mining operations located in Nunavut, Canada (the “Nunavut Collaboration Agreement”).
Sale of Interest in Fingold
B2Gold has agreed to sell its 70% interest in Fingold, which owns several exploration claims adjacent to Rupert Resources’ Ikkari Project located in Northern Finland,...
USA Rare Earth Announces Definitive Agreement to Acquire Serra Verde Group for ~$2.8 Billion, Creating the Global Rare Earth Leader
Written by Customer Service on . Posted in Mergers And Acquisitions.
Secures One of the Industry’s Most Strategic Operations as the Only Scaled Producer of all Four Magnetic Rare Earth Elements Outside Asia, along with a 15-Year 100% Offtake Agreement with a Special Purpose Vehicle Capitalized by Various U.S. Government Parties, as well as Private Capital Sources and Including Specific Price Floors for Nd, Pr, Dy and Tb
Serra Verde Expected to Deliver $550-$650 million of Annualized Run-Rate EBITDA by the end of 20271; Combined Company Expected to Generate c.$1.8 billion of EBITDA in 2030
Combined Company Benefits from a Robust Balance Sheet with Pro-forma Liquidity of c.$3.2 billion2
Best-in-Class Capabilities Across Mining, Processing, Separation, Metallization and Magnet Making with Broad-Based Support from Multiple U.S. Government Agencies and Allies
Further Strengthens USA Rare Earth’s Leadership...
NEURONES: Declaration of transactions on treasury shares (April 13 to 17, 2026)
Written by Customer Service on . Posted in Public Companies.
Nanterre, April 20, 2026
Declaration of transactions on treasury shares(period from April 13 to 17, 2026)
As part of the share buyback program authorized by the General Meeting of June 5, 2025 and entrusted to CIC, NEURONES made the following purchases between April 13 and 17, 2026 (ISIN code FR0004050250):Day
Total daily volume(in number of shares)
Weighted average price(unit daily)04/13/2026
6,515
€36.0904/14/2026
6,723
€36.7304/15/2026
6,572
€36.6604/16/2026
5,443
€37.0304/17/2026
22,032
€37.77Total
47,285
As of April 17, 2026, excluding the liquidity contract, NEURONES now holds 381,250 of the 24,328,716 shares comprising the company’s capital (i.e., 1.57%).
All press releases relating to the share buyback program are published in the “Regulated Information” section (under “Weekly declarations...
Aktsiaselts Infortar Investor Webinar introducing the results of the Q1 2026
Written by Customer Service on . Posted in Public Companies.
Infortar will organize a webinar for investors on 4 May 2026 at 12:00 (EET) in Estonian and at 14:00 (EET) in English to introduce the first quarter 2026 results. The webinar will be attended by the Managing Director Martti Talgre and Investor Relations Manager Kadri Laanvee.
The webinar will be hosted on the Microsoft Teams platform. Please note that to participate, no prior registration is required, and no reminder of the webinar will be sent. You can either participate by joining from your web browser or via Microsoft Teams application. When using a smart device to join the webinar, you first need to download the Microsoft Teams application from either Play Store or App Store.
Please join the webinar via the following links:
4 May at 12:00 (EET) Estonian webinar4 May at 14:00 (EET) English webinar
Questions can be sent to investor@infortar.ee before...
AL Sydbank A/S share buyback programme: transactions in week 16
Written by Customer Service on . Posted in Public Companies.
Company Announcement No 19/2026Peberlyk 46200 AabenraaDenmark
Tel +45 74 37 37 37
AL Sydbank A/SCVR No DK 12626509, Aabenraaal-sydbank.com20 April 2026
Dear Sirs
AL Sydbank A/S share buyback programme: transactions in week 16On 25 February 2026 AL Sydbank A/S announced a share buyback programme of DKK 1,100m. The share buyback programme commenced on 2 March 2026 and will be completed by 31 January 2027.
The purpose of the share buyback programme is to reduce the share capital of AL Sydbank A/S and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules.
The following transactions have been made under...
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Written by Customer Service on . Posted in Public Companies.
Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1
Haemoglobin response was superior with etavopivat: 48.7% of people on treatment achieved an increase of >1g/dL after 24 weeks versus 7.2% on placebo1
Novo Nordisk plans to submit for the first regulatory approval of etavopivat in the second half of 2026Bagsværd, Denmark, 20 April 2026 – Novo Nordisk today announced the topline results from HIBISCUS, a pivotal phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD). The results showed that etavopivat successfully met both co-primary endpoints, demonstrating superior reduction in vaso-occlusive crises (VOCs) and superior improvement in haemoglobin (Hb) response compared to placebo.
Etavopivat...
WeRide’s WRD 3.0 Makes History as the Only Four‑Time Champion at China Urban Intelligent Driving Competition
Written by Customer Service on . Posted in Public Companies.
WUHU, China, April 20, 2026 (GLOBE NEWSWIRE) — At the Wuhu round of the Second China Urban Intelligent Driving Competition hosted by D1EV, a leading media platform in the electric and intelligent vehicle sector, the Chery Exeed Sterra ET – equipped with the one‑stage end‑to‑end ADAS (Advanced Driver Assistance System) solution jointly developed by WeRide and Bosch – secured first place by over 10 points, with Horizon Robotics and XPeng taking second and third place.
With this victory, WeRide Driving (WeRide WRD 3.0) becomes the first and only solution in the competition’s history to achieve four consecutive wins, reinforcing its technological leadership in complex urban driving environments.WeRide Driving (WRD 3.0) is the first and only solution to achieve four consecutive wins in the Second China Urban Intelligent Driving Competition
From...
Consensus estimates ahead of Q1 2026
Written by Customer Service on . Posted in Public Companies.
Alm. Brand Group hereby publish consensus estimates prior to the announcement of the Q1 results.
Consensus estimates are also available via: almbrand.dk
Conference Call
Alm. Brand Group will report its Q1 2026 results on 28 April at 07:30 CEST and host a conference call with management at 11:00 CEST on the day of release.
Dial in for analysts and investors (Conference ID: 177147878):
Denmark: +45 80 83 03 77
UK: +44 117 389 0104
USA: +1 585 542 9983
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Mads Thinggaard – Head of Investor Relations & ESG – mobile no. +45 2025 5469
Press:
Mikkel Luplau Schmidt – Head of Communications and Media Relations – mobile no. +45 2052 3883AttachmentsALMB consensus Q126 and 2026_2028
...
Form 8.3 – [ANIMALCARE GROUP PLC – 17 04 2026] – (CGWL)
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
ANIMALCARE GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
N/A(e) Date position...
